drugset / Trial / NCT02516085

Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and Metformin

NCT02516085

Phase 1 Completed 5 enrolled University Hospital, Basel, Switzerland
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to show that the intake of L-arginine and metformin improves muscle function and delays disease progression in patients with Duchenne's muscular dystrophy.

Timeline

Start
2012-01
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject L-arginine Small molecule 2.5 g Oral
Subject Metformin Small molecule 250 mg Oral